픽시스 온콜로지(PYXS)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.33 (-2.35%), 시가총액 $0.17B, 52주 최저~최고 $1.04 ~ $5.34.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat
픽시스 온콜로지의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
픽시스 온콜로지의 현재 주가는 $3.33 (-2.35%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
픽시스 온콜로지의 시가총액은 약 $0.17B입니다.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigation